Compare Bristol-Myers Squibb Co (BMY) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Prologis Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Prologis Inc trades at $142.49 (market cap $132.85B). The key difference: Bristol-Myers Squibb Co and Prologis Inc are close in size by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | PLD | |
|---|---|---|
Market Cap | $116.30B | $132.85B |
Sector | Health | Real Estate |
52-Week High | $62.37 | $148.74 |
52-Week Low | $42.60 | $104.08 |
Enterprise Value | $152.24B | $166.72B |
Dividend Yield | 4.42% | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Prologis (PLD) trades at $142.16, up 0.92% today, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.05 exceeding expectations of $0.806. Recent news highlights expansion into data centers and a rejected $16.9 billion bid for Segro, indicating aggressive growth ambitions. Cash flow trends show operational strength despite a net outflow in 2025, while debt-to-asset ratios have risen to 37.2%.
The outlook remains positive with a consensus price target of $155.20, offering ~9% upside. Key risks include rising leverage, execution challenges in new segments, and macroeconomic sensitivity. Institutional sentiment is bullish, but investors should monitor debt levels and integration of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
